Acute coronary syndrome (ACS) refers to a range of conditions associated with sudden, reduced blood flow to the heart, often resulting in myocardial infarction. According to Benjamin Stark et al., 2024, in 2022, there were 315 million prevalent cases of coronary artery disease globally. It accounted for a significant proportion of cardiovascular-related hospitalizations worldwide. According to the acute coronary syndrome pipeline analysis by Expert Market Research, numerous acute coronary syndrome therapeutics are under development, aimed at improving outcomes and reducing mortality. The growing focus on targeted therapies, personalized medicine, and novel drug delivery systems is expected to fuel growth in the coming years.
Major companies involved in the acute coronary syndrome pipeline analysis include Biotronik SE & Co. KG, DalCor Pharmaceuticals, and others.
Leading drugs currently in the pipeline include MT1002, and UDP-003, among others.
The acute coronary syndrome drug pipeline is expected to grow due to rising clinical trials targeting antiplatelet and anticoagulant therapies and increasing R&D in lipid-lowering and inflammation-modulating agents.
The Acute Coronary Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute coronary syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute coronary syndrome. The acute coronary syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute coronary syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute coronary syndrome treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute coronary syndrome.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acute coronary syndrome (ACS) refers to a group of conditions caused by a sudden reduction or blockage of blood flow to the heart, typically due to the rupture of an atherosclerotic plaque and subsequent clot formation. This leads to insufficient oxygen supply to the heart muscle, potentially causing chest pain, heart damage, or heart attack.
Acute coronary syndrome is treated with medications like antiplatelets, statins, beta-blockers, and anticoagulants, along with procedures such as angioplasty or coronary artery bypass grafting to restore blood flow. A study by Dr. Ravi Vazirani Ballesteros et al., 2024, highlighted that long-term management after acute coronary syndrome should include extended dual antiplatelet therapy, intensified lipid-lowering with PCSK9 inhibitors, and beta-blockers for patients with reduced ejection fraction, aligning with the 2023 ESC Guidelines to reduce recurrent cardiovascular events.
Acute coronary syndrome (ACS) continues to pose a major global health challenge, primarily driven by coronary artery disease (CAD). According to Benjamin Stark et al., 2024, an estimated 315 million people were living with CAD in 2022. Central Europe, Eastern Europe, and Central Asia reported the highest age-standardized prevalence rates, while South Asia had the lowest. To address the growing burden, pharmaceutical advancements and active drug pipeline developments are underway, aiming to improve treatment outcomes and reduce disease impact.
This section of the report covers the analysis of acute coronary syndrome drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total acute coronary syndrome clinical trials, at 50%, reflecting strong post-marketing commitments and long-term safety studies. Phase III accounts for 25%, showcasing robust late-stage developments. Phase II contributes 19%, indicating promising mid-stage innovations. This balanced pipeline is set to positively advance the treatment pipeline for acute coronary syndrome.
The drug molecule categories covered under the acute coronary syndrome pipeline analysis include small molecules, monoclonal antibodies, peptides, biologics, RNA-based therapies, gene therapies, and others. The acute coronary syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute coronary syndrome. Factor XIa inhibitors are emerging as a promising drug class for safer anticoagulation in acute coronary syndrome management. For instance, Milvexian, an oral Factor XIa inhibitor, is currently being evaluated in the Phase 3 LIBREXIA-ACS trial. This investigational therapy aims to reduce the risk of major adverse cardiovascular events by selectively inhibiting the coagulation pathway without increasing bleeding complications.
The EMR report for the acute coronary syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acute coronary syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acute coronary syndrome clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute coronary syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute coronary syndrome drug candidates.
MT1002, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd., is currently undergoing a Phase 2 clinical trial to evaluate its safety and efficacy in subjects with acute coronary syndrome undergoing PCI. This synthetic 32-amino acid peptide combines the actions of a direct thrombin inhibitor and a glycoprotein IIb/IIIa receptor antagonist. The study is examining MT1002’s antithrombotic potential, while minimizing bleeding risks through controlled dose escalation.
UDP-003 is Cyclarity Therapeutics’ lead candidate targeting 7-ketocholesterol, a toxic oxidized cholesterol involved in plaque buildup. Currently undergoing an early Phase 1 placebo-controlled trial, the study is evaluating the safety, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses in healthy participants and patients with acute coronary syndrome. The drug is being administered intravenously to stimulate macrophages for plaque reduction and vascular repair.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acute Coronary Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute coronary syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute coronary syndrome collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share